X

    XTL Biopharmaceuticals Ltd ADR (XTLB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.48
    +0.01 (+0.40%)

    Market Cap: $6.07M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Sep 25
    		$-0.01$0.00N/AMiss+92.3%
    Mar 25
    		$0.00$0.00N/ABeat-100.0%
    Dec 24
    		$-0.12N/AN/ABeat-123.8%
    Sep 24
    		$-0.04N/AN/ABeat-11.6%
    Jun 24
    		$-0.13N/AN/ABeat-93.4%
    Mar 24
    		$0.09N/AN/ABeat+152.8%
    Dec 23
    		$-0.05$0.00N/AMiss+62.1%
    Sep 23
    		$-0.04$0.00N/AMiss+73.8%
    Jun 23
    		$-0.07$0.00N/AMiss-27.7%
    Mar 23
    		$-0.17$0.00N/AMiss-1397.7%
    Dec 22
    		$-0.14$0.00N/AMiss-134.6%
    Sep 22
    		$-0.15$0.00N/AMiss-0.1%
    Jun 22
    		$-0.05N/AN/ABeat-3386.7%
    Mar 22
    		$0.01N/AN/ABeat+690.9%
    Dec 21
    		$0.40N/AN/ABeat+79160.0%
    Sep 21
    		$-0.15N/AN/ABeat-3860.5%
    Jun 21
    		$-0.00N/AN/ABeat-36.4%
    Mar 21
    		$-0.00N/AN/ABeat-4.8%
    Dec 20
    		$0.00N/AN/ABeat+400.0%
    Sep 20
    		$-0.00N/AN/ABeat-280.0%
    Jun 20
    		$-0.00N/AN/ABeat+89.0%
    Mar 20
    		$-0.00N/AN/ABeat-121.0%
    Dec 19
    		$0.00N/AN/ABeat-98.7%
    Sep 19
    		$-0.00N/AN/ABeat-150.0%
    Jun 19
    		$-0.01N/AN/ABeat-600.0%
    Mar 19
    		$0.01N/AN/ABeat+9900.0%
    Dec 18
    		$0.01$0.00N/ABeat+341.2%
    Sep 18
    		$0.00N/AN/ABeat-99.4%
    Jun 18
    		$0.00N/AN/ABeat-35.5%
    Mar 18
    		$0.00N/AN/ABeat+103.7%
    Dec 17
    		$0.00$0.00N/ABeat+158.6%
    Sep 17
    		$0.31N/AN/ABeat+408.6%
    Jun 17
    		$0.00N/AN/ABeat-
    Mar 17
    		$-0.00N/AN/ABeat-
    Dec 16
    		$-0.00N/AN/ABeat-
    Sep 16
    		$-0.10$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-2.07EV/EBITDA16.88x
    Price/FCF-2.66xFCF Yield-37.62%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-29.30%ROIC-10090.93%
    Financial Health
    Debt/Equity-1.06xInterest Coverage-13.31x
    Current Ratio0.40xQuick Ratio0.40x
    Trading Statistics
    Beta0.46Avg Volume10.77K
    52-Week High$10.2852-Week Low$2.01

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.71
    SMA 20$2.75
    SMA 50$2.79
    SMA 200$2.93
    EMA 10$2.63
    EMA 20$2.71
    EMA 50$2.74
    EMA 200$3.13

    MACD

    Line: -0.08Signal: -0.03Hist: -0.04

    ADX

    ADX: 16.5+DI: 20.4-DI: 19.5

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down88.0
    PSAR$3.37

    Bollinger Bands

    Upper Band$3.12
    Lower Band$2.38
    %B Position2716%(Upper)
    Band Width0.14

    RSI (14-Day)

    Neutral
    40.3

    Momentum Oscillators

    Stoch %K13.7
    Stoch %D15.0
    Williams %R-88.9
    ROC (10d)-4.6%
    Momentum-0.12
    CCI (20d)-130.4
    MFI (14d)65.2

    Volatility Measures

    ATR (14d)$0.24(9.6%)
    StdDev (20d)0.19
    Hist Vol108.2%(High)

    Volume Flow

    VWAP$2.50
    OBV197.6M
    AD Line175263061282.4B
    CMF (20d)0.216

    Volume Metrics

    Avg Vol (20d)11.1K
    Vol Ratio0.7x
    VWMA (20d)$2.96

    Pivot Points

    R3$2.85
    R2$2.78
    R1$2.62
    Pivot Point$2.55
    S1$2.39
    S2$2.32
    S3$2.16

    Advanced Oscillators

    TSI-10.03
    Ultimate Osc46.2
    KST-50.75

    Financial Data

    QuarterMar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022
    Total Revenue$289,000$289,000$162,000$0$0$0$0$0$0$-459,000$0$0
    Cost of Revenue$332,000$332,000$116,000N/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross Profit$-43,000$-43,000$162,000N/AN/AN/AN/AN/AN/A$-459,000N/AN/A
    Operating Expenses$769,000$1.10M$926,000$421,000$175,000$333$151,000$163,000$251,000$225,000$204,000$202,000
    R&D$32,000$32,000$54,000$6,000$6,000$6$6,000$6,000$13,000$6,000$3,000$15,000
    SG&A$812,000$706,000$472,000$415,000$169,000$194$145,000$157,000$238,000$219,000$201,000$187,000
    Operating Income$-812,000$-812,000$-764,000$-421,000$-175,000$-200$-151,000$-163,000$-251,000$-225,000$-204,000$-202,000
    Interest Income$0$2,000$13,000$9,000$10,000$11,000$9,000$9,000$12,000$16,000$0$5,000
    Interest Expense$36,000$94,000$93,000$13,000$16,000$84$28,000$32,000$25,000$30,000$10,000$11,000
    Income Before Tax$-385,000$-385,000$-553,000$-704,000$485,000$-284$-215,000$-364,000$-919,000$-748,000$-821,000$-285,000
    Income Tax Expense$-130,000$0$0$0$931,999$0$19,000$23,000$13,000$-27,000$-10,000$6,000
    Net Income$-255,000$-255,000$-553,000$-704,000$485,000$-284$-215,000$-364,000$-919,000$-748,000$-821,000$-285,000
    EBITDA$-429,250N/A$-156,000$-691,000$485,000$-199,750$-142,000$-154,000$-239,000$-224,750$-269,000$-197,000
    EBIT$-479,000N/A$-460,000$-421,000$310,000$-200,000$-142,250$-154,250$-239,250$-225,000$-269,250$-197,250
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XTLB

    News

    Enterprise value to revenue forward of XTL Biopharmaceuticals Ltd. – TASE:XTLB

    This article provides financial information for XTL Biopharmaceuticals Ltd. (TASE: XTLB), specifically focusing on its enterprise value to revenue forward. It indicates the stock's status as market closed with no trades on the Tel Aviv Stock Exchange. The content appears to be a financial data snippet from TradingView.

    TradingView•8/23/26•
    Neutral

    XTL Biopharmaceuticals Ltd. Revenue Breakdown – TASE:XTLB

    This page provides financial information for XTL Biopharmaceuticals Ltd. (TASE:XTLB) on the Tel Aviv Stock Exchange. It includes an overview of the company's financials, statistics, dividends, earnings, and segment performance, but no actual data is displayed, only navigational links to these sections.

    TradingView•8/22/26•
    Neutral

    XTLB Financials: Revenue Breakdown, Margins & Competitor Comparison

    This article provides a financial overview of X T L Biopharmaceuticals Ltd (XTLB), detailing its revenue breakdown, profitability margins, and a comparison with competitors. XTLB generates most of its revenue from Operating Segment / Medical Devices, with a negative contribution of -$589.00K. The company's profitability metrics like gross, operating, and net margins are not available, and it has a negative Return on Equity (ROE) of -29.30%.

    Intellectia AI•8/8/26•
    Somewhat-Bearish

    [6-K] XTL BIOPHARMACEUTICALS LTD Current Report (Foreign Issuer)

    XTL Biopharmaceuticals Ltd. (XTLB) has filed a Form 6-K reporting that a shareholder has initiated a motion for court authorization to file a derivative claim against the company's controlling shareholder and certain current and former directors and officers. The motion alleges breaches of duty in connection with the 2024 acquisition of The Social Proxy Ltd., including failures to fund the subsidiary, conflicts of interest, and delayed disclosures, seeking approximately NIS 100 million in damages. XTL Biopharmaceuticals believes the motion is meritless and intends to fully respond.

    Stock Titan•8/5/26•
    Bearish

    XTL Biopharmaceuticals Ltd. Revenue Breakdown – NASDAQ:XTLB

    This article provides a financial overview of XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) through TradingView. It offers access to the company's financials, news, community insights, and technical analysis data. The page is designed for investors to research XTL Biopharmaceuticals Ltd.'s performance and segments.

    TradingView•8/4/26•
    Neutral

    Frequently Asked Questions About XTLB

    Does XTLB pay dividends?
    XTL Biopharmaceuticals Ltd ADR (XTLB) does not currently pay a regular dividend.
    What is XTLB's market cap?
    XTL Biopharmaceuticals Ltd ADR (XTLB) has a market capitalization of $6.07M with a current stock price of $2.48.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In